Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2003
08/07/2003WO2003032728A8 Methods for preventing or reversing asthma and compositions useful therefor
08/07/2003WO2003030829A3 Liposome-encapsulated insulin formulations
08/07/2003WO2003030826A3 Antisense modulation of insulin-like growth factor binding protein 5 expression
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2003025000A3 Peptides capable of modulating immune response
08/07/2003WO2003020911A9 Human schizophrenia gene
08/07/2003WO2003018788B1 Improved nitroreductase enzymes
08/07/2003WO2003015615A9 Treatment of muscular dystrophies and related disorders
08/07/2003WO2003008640A3 Asthma-associated gene
08/07/2003WO2003006689A3 Diagnosis and treatment of diseases associated with altered expression of hipk1
08/07/2003WO2003004034B1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
08/07/2003WO2002088334A9 Chimeric immunoreceptor useful in treating human cancers
08/07/2003WO2002068476A3 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
08/07/2003WO2002066642A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/07/2003WO2002064157A3 Localized myocardial injection method for treating ischemic myocardium
08/07/2003WO2002057457A3 Human proteins 55562 and 21617, and methods of use thereof
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002048340A3 Transgenci mice containing cashgene disruptions
08/07/2003WO2002048192A3 Amidated glucagon-like peptide-1
08/07/2003WO2002045659A9 Novel therapeutics for heart failure and aging
08/07/2003WO2002033119A3 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
08/07/2003WO2002030259A9 Disease prevention by reactivation of the thymus
08/07/2003WO2002024222A3 Ligands for g protein coupled receptors and methods of using them
08/07/2003WO2002020751A3 Hyperglycosylated polypeptides
08/07/2003WO2002018608A9 Methods for enhancing the efficacy of cancer therapy
08/07/2003WO2002015921A3 Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
08/07/2003WO2002013867A3 Augmented cognitive training
08/07/2003WO2002012331A3 Compositions and methods for the therapy and diagnosis of pancreatic cancer
08/07/2003WO2002004015A9 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003WO2001066773A3 Nucleic acids that code for oxidosqualene cyclases
08/07/2003WO2001057252A3 Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
08/07/2003US20030150005 Rodent model comprising genes coding hypoxia inducible factor (HIF) for detection of hypoxic tissue
08/07/2003US20030150003 Novel apolipoprotein gene involved in lipid metabolism
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149531 Serpentine transmembrane antigens expressed in human cancers and uses thereof
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149256 Transferrin polynucleotides, polypeptides, and antibodies
08/07/2003US20030149249 Process for isolation of osteopontin from milk
08/07/2003US20030149247 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
08/07/2003US20030149246 Macromolecular conjugates and processes for preparing the same
08/07/2003US20030149245 Chimeric protein for detection of enzymtic polypeptides; immunoassays
08/07/2003US20030149244 Adjusting affinity of Fab 27/26 fragments/polypeptides generating improved ragweed-induced histamine release inhibition; bronchodilator agents
08/07/2003US20030149242 Novel polypeptide
08/07/2003US20030149241 Nucleotide sequences coding osteogenic protein for induction/differentiation and/or treatment of bone, cartilage and other connective tissue defects; wound healing agents
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149236 Nucleotide sequences coding interleukin (IL)-11 receptor for development of agonists, antagonists, therapeutic and diagnostic reagents; antiproliferative/inflammatory agents
08/07/2003US20030149235 Peptide complex comprising expression vector for transfer of heterologous polynucleotides to endothelial cells; gene therapy; drug delivery
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149090 Topically delivering an effective dose of a reactvie oxygen metabolites (ROM) production and release inhibitory compound in carrier to a subject suffering from ROM-mediated oxidative damage
08/07/2003US20030149076 Administering drug formulation comprising opioidergic agent and an insulin secretagogue for therapy of human suffering from one or more conditions included within Coronary Heart Disease Risk Factor Syndrome
08/07/2003US20030149049 Small-molecule inhibitors of interleukin-2
08/07/2003US20030149022 Inhibiting beta -amyloid peptide release and/or its synthesis in a cell by administering deoxyamino acid compound
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149004 Antibacterial activity
08/07/2003US20030148989 For therapy of non small cell lung cance, non-Hodgkin's lymphoma in humans
08/07/2003US20030148988 Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats
08/07/2003US20030148987 Selective 11beta-HSD inhibitors and methods of use thereof
08/07/2003US20030148986 For therapy of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148984 Molecular chemotherapy enhancement of radiotherapy
08/07/2003US20030148983 Polynucleotide therapy
08/07/2003US20030148979 Traversal of nucleic acid molecules through a fluid space and expression in repair cells
08/07/2003US20030148978 Oligonucleotides antisense to mouse pituitary tumor transforming gene carboxy-terminal (PTTG-C) and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
08/07/2003US20030148977 Delivering to mammalian cell that overexpresses pituitary tumor transforming gene carboxy-terminal (PTTG-C) formulation comprising polynucleotide to allow the polynucleotide to enter the cell, whereby expression of PTTG protein is prevented
08/07/2003US20030148976 For therapy of cancer, infectious disease, and allergic disorders
08/07/2003US20030148974 Antisense modulation of akt-3 expression
08/07/2003US20030148972 Hereditary hemochromatosis gene
08/07/2003US20030148971 Treatment of inflammatory and malignant diseases
08/07/2003US20030148969 Antisense modulation of mucin 1, transmembrane expression
08/07/2003US20030148968 Delivering a transgene encoding an angiogenic protein or peptide to myocardium of patient by introducing a vector comprising transgene into coronary artery, wherein the transgene is is delivered to the myocardium and expressed
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148959 Anti-aging and wound healing compounds
08/07/2003US20030148958 For therapy and prophylaxis of muscular dystrophy
08/07/2003US20030148957 Corticotropin releasing factor 2 receptor agonists
08/07/2003US20030148956 For therapy and prophylaxis of muscular dystrophy
08/07/2003US20030148955 Administering a soluble TNF alpha receptor-binding inhibitorpreferably TNFR:fc; preventing or reducing resistance to imatinib in a chronic myelogenous leukemia patient or to urocortin 1 in a patient with gastrointestinal cancer
08/07/2003US20030148954 Agents and methods for modulating activator protein-1-mediated cellular processes
08/07/2003US20030148953 Inactivation resistant factor VIII
08/07/2003US20030148952 Recruiting endothelial precursor cells (bone marrow-derived angioblasts) to a wound site by administering angiopoietin-1; to enhance angiogenesis and the maintenance of organ transplants; wound healing agents; gene therapy
08/07/2003US20030148951 Human EMR2, a G-protein coupled receptor from the EGF_TM7 family
08/07/2003US20030148950 Kringle domain 1 of human hepatocyte growth factor and uses therefor
08/07/2003US20030148949 Administering a trefoil peptide or biologically active fragment thereof to a skin lesion or region of the skin where a lesion is to be prevented; wound healing agents which can speed healing, reduce pain and delay/prevent lesions
08/07/2003US20030148948 Super-active porcine growth hormone releasing hormone analog
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148945 Antimicrobial and anti-inflammatory peptides
08/07/2003US20030148944 Triple polypeptide complexes
08/07/2003US20030148943 Novel tachykinin-like polypeptides and use thereof
08/07/2003US20030148942 Administering enkephalin peptides on an intermittent dose schedule to promote a sustained increased level of T-cell production in immunocompromised subjects; anticarcingenic agents; viricides; bactericides; fungicides; parasiticides
08/07/2003US20030148940 CXCR4 agonist treatment of hematopoietic cells
08/07/2003US20030148939 Compositions and methods related to claudin-7
08/07/2003US20030148938 Aqueous sustained-release formulations of proteins
08/07/2003US20030148937 Methods and compositions for use in spliceosome mediated RNA trans-splicing
08/07/2003US20030148936 Bioactive peptides
08/07/2003US20030148935 Novel nuclear factor polypeptides and nucleic acids encoding same
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030148933 Isolation of dehydrodidemnin B, a cyclic depsipeptide, from a tunicate of the Ascidiacea class; anticarcinogenic agents; antitumor agents; viricides; cytolysis; amidation of Didemnin A by 1-(pyruvyl)pyrridine-2-carboxylic acid
08/07/2003US20030148930 Human zona pellucida proteins and methods of their use in diagnoising male infertility
1 ... 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 ... 3163